Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
The Cell Cycle Control System01:28

The Cell Cycle Control System

3.5K
The cell cycle regulation directs how a cell proceeds from one phase to the next and begins mitosis. The cell cycle control system includes intracellular regulatory molecules and external triggers. They provide "stop" or "advance" signals and operate at specific cell cycle stages termed checkpoints to ensure that a particular process is completed before the cell advances to the next phase.
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...
3.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Negative Regulator Molecules01:23

Negative Regulator Molecules

35.9K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.9K
Positive Regulator Molecules02:39

Positive Regulator Molecules

5.7K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

USP24 is a cross-reactive DUB targeting MOV10 to regulate IFN-I production.

Nature communications·2026
Same author

Multidimensional proteomics and explainable AI feature selection identify cross-platform lung cancer molecular signature in blood plasma.

Communications medicine·2026
Same author

Targeted Intracellular Delivery of Amino Acids to Trophoblast Cells Reveals Proteomic Signatures of Cellular Utilisation.

Biomolecules·2026
Same author

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Nature medicine·2026
Same author

Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion.

bioRxiv : the preprint server for biology·2026
Same journal

Inside the new political screening that's stalling NIH grants.

Nature·2026
Same journal

Europe's record heatwave: does the continent have a new climate?

Nature·2026
Same journal

Daily briefing: Humans and great apes giggle in the same rhythms.

Nature·2026
Same journal

The surprising career parallels between footballers and researchers.

Nature·2026
Same journal

I study World Cup penalty shoot-outs: they say a lot about the psychology of performance under pressure.

Nature·2026
Same journal

CRISPR's next act: the companies editing the epigenome to treat disease.

Nature·2026
See all related articles

Related Experiment Video

Updated: Sep 10, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors.

Shilpa Singh1, Catherine E Gleason2, Min Fang3

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Nature
|August 20, 2025
PubMed
Summary
This summary is machine-generated.

New macrocyclic peptides selectively kill small-cell lung cancer (SCLC) cells by inhibiting cyclin interactions. These orally available drugs target E2F-driven cancers by inducing apoptosis through spindle assembly checkpoint activation.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

27.6K

Related Experiment Videos

Last Updated: Sep 10, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

27.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Small-cell lung cancer (SCLC) is characterized by mutations in RB1 and TP53, leading to dysregulated E2F activity.
  • Hyperactivation of E2F, while essential for cell cycle progression, can promote apoptosis, presenting a therapeutic vulnerability.
  • Targeting the cyclin-substrate interaction interface, specifically RxL motifs, has been challenging.

Purpose of the Study:

  • To develop novel cell-permeable, orally bioavailable macrocyclic peptides targeting cyclin RxL motifs.
  • To investigate the efficacy of these inhibitors in cancer cells with high E2F activity, including SCLC.
  • To elucidate the molecular mechanisms underlying the anti-cancer effects of these novel inhibitors.

Main Methods:

  • Development of dual inhibitors targeting cyclin A and cyclin B RxL motifs (cyclin A/Bi).
  • Assessment of selective killing of SCLC and other cancer cells with high E2F activity.
  • Utilizing genetic screens to identify mechanisms of apoptosis induction.
  • Investigating the role of cyclin B, CDK2, and spindle assembly checkpoint activation.
  • Evaluating anti-tumor activity in chemotherapy-resistant SCLC patient-derived xenografts.

Main Results:

  • Cyclin A/Bi selectively kills SCLC and other cancer cells with high E2F activity.
  • Apoptosis is induced via cyclin B- and CDK2-dependent spindle assembly checkpoint activation.
  • Cyclin A/Bi blocks cyclin A-E2F and cyclin B-MYT1 RxL interactions, leading to E2F and cyclin B hyperactivation.
  • Neomorphic cyclin B-CDK2 complexes are formed, driving mitotic cell death.
  • Orally administered cyclin A/Bi demonstrated significant anti-tumor activity in SCLC xenografts.

Conclusions:

  • Developed orally bioavailable macrocyclic peptides (cyclin A/Bi) that inhibit cyclin RxL interactions.
  • Cyclin A/Bi effectively targets E2F-driven cancers, including SCLC, by inducing apoptosis.
  • These findings support the therapeutic potential of cyclin A/Bi for treating chemotherapy-resistant SCLC and other cancers.